Pelacarsen

DB16284Investigational

Pelacarsen is under investigation in clinical trial NCT03070782 (Phase 2 Study of ISIS 681257 (Akcea-apo(a)-lrx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease).

Mechanism: Pharmacologically active on Apolipoprotein(a)
Curator reviewed
Also known as: AKCEA-APO(a)-LRx · IONIS-APO(a)-LRx · Isis-681257 (galnac3--conjugated aso targeting human lipoprotein (a)) free acid
Code names: ISIS-681257 FREE ACID · TQJ230

Resolves to

Compound

UNIILSO9H7UZ90CAS1637637-70-7

Targets

P08519LPA

What you can answer from here — as of March 28, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

15Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Pelacarsen, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account